Merck & Co Inc (MRK)

  • BCG Recommendation

Balfour Capital Group Researched  Merck and Co Inc on December 9th, 2022.

Merck & Co Inc (MRK) is a prominent pharmaceutical company, globally recognized for its innovative research and development of drugs and vaccines that contribute to medical advancements and public health.

View Research
More Buy Recommendations

Post Recommendation Price Trend Chart

  • The chart's commencement marks the instance of our stock recommendation.
  • We have established a Buy recommendation at $108.75 on December 9th, 2022.
  • Our designated price target stands at $145.00.

Analysts Research

Balfour Capital Group's unwavering commitment to comprehensive research involves esteemed analysts and companies, evident below, enhancing our expertise. This collaborative approach enriches findings, providing profound insights into our recommendations and research objectives.
BCG Logo (white)

Company Snapshot

Balfour Capital Group's precise and thorough research crafted by our team of analysts.

Our Research

View

Thomson Reuters on MRK

Thomson Reuters delivers global financial, legal, and business information to professionals.

Thomson Reuters Notes

View

Morgan Stanley on MRK

Morgan Stanley researches industries, offers insights to clients.

Morgan Stanley Notes

View
Balfour Capital Group wants to clarify that our recommendation to Buy Merck & Company, Inc (MRK) is based on thorough research conducted by our dedicated teams. We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance. However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.

*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
error: Content is protected !!